{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:57:05Z","timestamp":1770577025487,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","award":["201803D31119"],"award-info":[{"award-number":["201803D31119"]}],"id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017592","name":"Key Science and Technology Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2022XM05"],"award-info":[{"award-number":["2022XM05"]}],"id":[{"id":"10.13039\/501100017592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471618"],"award-info":[{"award-number":["81471618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971543"],"award-info":[{"award-number":["81971543"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.autrev.2023.103270","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T02:11:32Z","timestamp":1673057492000},"page":"103270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-dose interleukin-2 treatment increases the proportion of regulatory T cells in patients with rheumatic diseases: A meta-analysis"],"prefix":"10.1016","volume":"22","author":[{"given":"Huanhuan","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huer","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.autrev.2023.103270_bb0005","article-title":"Treg suppression of immunity within inflamed allogeneic grafts. JCI","volume":"7","author":"Dai","year":"2022","journal-title":"Insight"},{"issue":"19","key":"10.1016\/j.autrev.2023.103270_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2023.103270_bb0015","article-title":"Regulatory T cells in autoimmune Vasculitis","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103270_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2023.103270_bb0025","article-title":"IL-2-based approaches to Treg enhancement","author":"Harris","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2023.103270_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938556","article-title":"Increased sIL-2R\u03b1 leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2","volume":"13","author":"Long","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103270_bb0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2023.103270_bb0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to give new life to T cell immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.autrev.2023.103270_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108935","article-title":"New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases","volume":"110","author":"Jin","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103270_bb0050","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","article-title":"Interleukin-2 and regulatory T cells in rheumatic diseases","volume":"17","author":"Kolios","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2023.103270_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2022.113229","article-title":"TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3\/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones","volume":"503","author":"Kongkaew","year":"2022","journal-title":"J Immunol Methods"},{"issue":"9","key":"10.1016\/j.autrev.2023.103270_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002865","article-title":"High-dose IL-2\/CD25 fusion protein amplifies vaccine-induced CD4(+) and CD8(+) neoantigen-specific T cells to promote antitumor immunity","volume":"9","author":"Hernandez","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2023.103270_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.648408","article-title":"Low-dose IL-2 therapy in autoimmune and rheumatic diseases","volume":"12","author":"Gra\u00dfhoff","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103270_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.autrev.2023.103270_bb0075","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211011370","article-title":"Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis","volume":"13","author":"Zhang","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"10.1016\/j.autrev.2023.103270_bb0080","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2023.103270_bb0085","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103270_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103270_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jir.2018.0016","article-title":"Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus","volume":"39","author":"Shao","year":"2019","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"10.1016\/j.autrev.2023.103270_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","article-title":"Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study","volume":"23","author":"Miao","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2023.103270_bb0105","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/03007995.2022.2065145","article-title":"Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection","volume":"38","author":"Zhang","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.autrev.2023.103270_bb0110","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2023.103270_bb0115","first-page":"867","article-title":"Therapeutic responses and predictors of low-dose interleukin-2 in systemic lupus erythematosus","volume":"40","author":"Miao","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103270_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105912","article-title":"Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis","volume":"77","author":"Feng","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103270_bb0125","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40744-021-00301-3","article-title":"Treatment of active idiopathic inflammatory myopathies by low-dose Interleukin-2: A prospective cohort pilot study","volume":"8","author":"Miao","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"11","key":"10.1016\/j.autrev.2023.103270_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103186","article-title":"Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV\/CMV viremia","volume":"21","author":"Zheng","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2023.103270_bb0135","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2023.103270_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: A randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2023.103270_bb0145","article-title":"The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2","volume":"11","author":"Wang","year":"2020","journal-title":"Ther Adv Chron Dis"},{"issue":"9","key":"10.1016\/j.autrev.2023.103270_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103156","article-title":"Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis","volume":"21","author":"Wu","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2023.103270_bb0155","doi-asserted-by":"crossref","first-page":"746","DOI":"10.55563\/clinexprheumatol\/lnn76t","article-title":"Low-dose IL-2 effectively restored decreased regulatory T cells in patients with Beh\u00e7et\u2019s disease","volume":"39","author":"Liu","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103270_bb0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103270_bb0165","doi-asserted-by":"crossref","first-page":"1012868","DOI":"10.3389\/fimmu.2022.1012868","article-title":"Reestablish immune tolerance in rheumatoid arthritis","volume":"13","author":"Shuai","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103270_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103134","article-title":"New insights for regulatory T cell in lupus nephritis","volume":"21","author":"Li","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103270_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.750542","article-title":"Regulatory T cells: regulation of identity and function","volume":"12","author":"Grover","year":"2021","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.autrev.2023.103270_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.autrev.2023.103270_bb0185","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103270_bb0190","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5152\/dir.2021.20503","article-title":"High-dose interleukin-2 therapy related adverse events and implications on imaging","volume":"27","author":"Shah","year":"2021","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.autrev.2023.103270_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107836","article-title":"Interleukin-2 therapy of cancer-clinical perspectives","volume":"98","author":"Majidpoor","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103270_bb0200","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/art.42111","article-title":"Driving role of Interleukin-2-related regulatory CD4+ T cell deficiency in the development of lung fibrosis and vascular remodeling in a mouse model of systemic sclerosis","volume":"74","author":"Frantz","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"10.1016\/j.autrev.2023.103270_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103270_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102645","article-title":"Low-dose Interleukin-2: biology and therapeutic prospects in rheumatoid arthritis","volume":"19","author":"Wu","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2023.103270_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060980","article-title":"T cells, Interleukin-2 and systemic lupus erythematosus-from pathophysiology to therapy","volume":"11","author":"Mak","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.autrev.2023.103270_bb0220","first-page":"1809","article-title":"Cohort study of off-label use of low-dose IL-2 therapy for systemic autoimmune diseases","volume":"40","author":"Al Tabaa","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103270_bb0225","first-page":"1","article-title":"Comparative efficacy and safety of biological agents in the treatment of lupus nephritis: a network meta-analysis","author":"Lee","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.autrev.2023.103270_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102591","article-title":"Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis","volume":"117","author":"Buitrago-Molina","year":"2021","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2023.103270_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.08.015","article-title":"Low-dose IL-2 for treating moderate to severe alopecia Areata: A 52-week multicenter prospective placebo-controlled study assessing its impact on T regulatory cell and NK cell populations","volume":"141","author":"Le Duff","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2023.103270_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.604464","article-title":"Phenotyping of adaptive immune responses in inflammatory diseases","volume":"11","author":"Humrich","year":"2020","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:30:53Z","timestamp":1761600653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1568997223000046"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103270","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose interleukin-2 treatment increases the proportion of regulatory T cells in patients with rheumatic diseases: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103270"}}